Consonance Capital Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Consonance Capital Management’s Portfolio ARIA Stock Details ARIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-3,553,943	Closed	-$44.2M	–	29
2016 Q4	$44.2M	Sell	3,553,943 -5,141,799	-59%	-$61.9M	4.86%	9
2016 Q3	$119M	Sell	8,695,742 -150,000	-2%	-$1.51M	11.46%	2
2016 Q2	$65.4M	Buy	8,845,742 +3,270,000	+59%	+$24.5M	9.25%	3
2016 Q1	$35.6M	Buy	+5,575,742	New	+$31.3M	5.39%	11
2014 Q1	–	Sell	-12,260	Closed	-$84K	–	34
2013 Q4	$84K	Sell	12,260 -292,200	-96%	-$1.58M	0.01%	27
2013 Q3	$5.6M	Sell	304,460 -1,026,640	-77%	-$19.9M	1.4%	20
2013 Q2	$23.3M	Buy	+1,331,100	New	+$23.6M	8.28%	5

Other funds holding ARIA

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Consonance Capital Management's ARIA Position: Q1 2017 in Review

Consonance Capital Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 3,553,943 shares — an estimated $44.2M sold.

Consonance Capital Management first reported a position in ARIA in Q2 2013 and held it in 7 quarters. The position peaked at $119M in Q3 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

Consonance Capital Management reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
Consonance Capital Management sold 3,553,943 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $44.2M.
Consonance Capital Management first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 7 quarters.
Consonance Capital Management's Ariad Pharmaceuticals Inc position peaked at $119M in Q3 2016.
1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Consonance Capital Management's 13F filing for Q1 2017, filed 15 May 2017.